On September 28, the Chengdu Industrial Boutique Release & Supply-Demand Matching Conference with the theme of “Supply-Demand Collaboration, Co-creating Boutiques” was grandly held in Chengdu. The Haemophilus influenzae type b conjugate vaccine (Hib vaccine) of Chengdu Olymvax Biopharmaceuticals Inc. (hereinafter referred to as “Olymvax”) was honorably selected and successfully included in the new list of “Chengdu Industrial Boutiques”. This is the second time the Company has stood out in this authoritative selection after its adsorbed tetanus vaccine won this honor, fully demonstrating the Company’s profound heritage and hard-core strength in vaccine R&D and quality control.
As the core starting point to promote the brand building of “Chengdu Intelligent Manufacturing”, the selection of Chengdu Industrial Boutiques aims to guide local enterprises to deeply engage in “Increasing Varieties, Improving Quality, Creating Brands”, strive to build an internationally influential urban industrial business card, and accelerate the cultivation of benchmarking blockbuster products of “Chengdu Made”.
The Hib vaccine selected this time is an important vaccine variety to protect children’s health. This product adopts the independently developed Hib strain production medium formula, fermentation process and carrier protein conjugation process of Olymvax, successfully solving the problems of low yield of Haemophilus influenzae type b capsular polysaccharide, complex vaccine production process and low content of high-molecular conjugates, reducing the difficulty of vaccine industrialization. Its overall technical level is leading in China, and it was recognized as the “2020 Chengdu Major Innovative Product” by Chengdu Science and Technology Bureau.
It is worth mentioning that the adsorbed tetanus vaccine selected last year also has an excellent market performance, having ranked first in domestic market share for seven consecutive years and continuously leading the industry. The re-certification of Hib vaccine is another high recognition of Olymvax’s comprehensive strength by the industry and government departments. With more than ten years of deep cultivation in the vaccine field, Olymvax has successfully launched 3 products to the market; meanwhile, the Company has continued to make efforts in the “super bacteria” and adult vaccine tracks, with a number of global Class 1.1 new drugs under research, among which the recombinant Staphylococcus aureus vaccine has completed Phase III clinical enrollment, with leading technical level and R&D progress globally.
The successful selection of Hib vaccine is not only another milestone in Olymvax’s own development, but also demonstrates the strong momentum of “Chengdu Made” vaccines on the road of high-quality development. In the future, Olymvax will continue to focus on vaccine R&D and innovation, continuously contribute to the global public health cause, and let more “Chengdu Boutique” vaccines go national and serve the world.